COMMUNIQUÉS West-GlobeNewswire

SurvivorRx Expands Personalized Supplement Routines as Oncologists Raise Concerns About Supplement Safety for Cancer Survivors
24/03/2026
New oncology- and naturopath-informed supplement systems aim to simplify post-treatment wellness while addressing safety, dosing, and formulation challenges many survivors face JACKSONVILLE, Fla., March 24, 2026 (GLOBE [...]
Lace-Up Ankle Brace Support Gets Comfort Upgrade and Removable Side Stabilizers
24/03/2026
Lynden, WASHINGTON, March 24, 2026 (GLOBE NEWSWIRE) -- Z Athletics has announced an upcoming updated version of its flagship lace-up ankle brace, featuring upgraded comfort materials and new removable semi-rigid side [...]
Compliance With Nasdaq Periodic Filing Requirement
24/03/2026
Singapore, March 24, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that based on the Company’s amended annual report on [...]
MINES and Associates COO Recognized as 2026 Colorado Titan 100 Recipient
24/03/2026
LITTLETON, Colo., March 24, 2026 (GLOBE NEWSWIRE) -- MINES and Associates (MINES) is proud to announce that its Chief Operating Officer, Myron Unruh, has been named a 2026 Colorado Titan 100 recipient, an honor that [...]
Serina Therapeutics to Present at the 38th Annual Roth Conference
24/03/2026
HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
24/03/2026
Inclusion in U.S. CRSP ® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world’s largest mutual fund Expands market presence across the [...]
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors
24/03/2026
Dortmund, Germany, March 24, 2026 – iDEL Therapeutics today announced the appointment of accomplished biopharmaceutical executive Claudia Ulbrich, MD, as the Chair of its Board of Directors. Dr. Ulbrich brings over 25 [...]
Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
24/03/2026
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration [...]
Transactions in connection with share buy-back program
24/03/2026
Company announcement no. 6 - 26 24 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Yatiri Bio Enters Exclusive Option to In-License Agreement with Oscotec for Denfivontinib in AML
24/03/2026
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop [...]
Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant
24/03/2026
March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025. Philips’ platform-based solutions [...]
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
24/03/2026
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
24/03/2026
VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
24/03/2026
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times [...]
Phonak AI-Powered Hearing Aids Recognized with 2026 Artificial Intelligence Excellence Awards
24/03/2026
Phonak Virto R Infinio and Phonak Infinio Ultra Sphere honored for advancing real-world hearing performance through AI innovation STÄFA, Switzerland, March 24, 2026 (GLOBE NEWSWIRE) -- Phonak , a global leader in [...]
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures Proceeds will [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
24/03/2026
Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients atteints d’une forme [...]
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
24/03/2026
Focused on selective acquisitions of high-quality companies in strategic industrial sectors MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge 1 , a strategic [...]
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
24/03/2026
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, [...]

Pages